Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Crispr Therapeutics Ag (NQ: CRSP )

50.76 +4.37 (+9.42%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Crispr Therapeutics Ag

< Previous 1 2 3 4 5 6 7 8 9
...
29 30 Next >
Cathie Wood Is Buying the Dip on These 2 Biotech Stocks. Should You?
In keeping with Cathie Wood's style, these picks are riskier than average. 
Via The Motley Fool
Cathie Wood Has Been Steadily Selling Shares of This Growth Stock. Should You?
Teladoc's share performance has reflected its earnings struggles... 
Via The Motley Fool
7 Stocks You Haven’t Heard of (That EVERYONE Should Own)
These under-the-radar must-own stocks across various sectors are using powerful megatrends and posting solid financial results. 
Via InvestorPlace
7 Biotech Stocks to Put on Your Breakthrough Radar
Although biotech stocks can present volatility risks due to its feast-or-famine nature, their narrative offers permanent relevance. 
Via InvestorPlace
3 Reasons to Buy CRISPR Therapeutics Stock Like There's No Tomorrow
There are a handful of different factors that could buoy its stock. 
Via The Motley Fool
Is CRISPR Therapeutics a Millionaire Maker?
The stars are aligning for it to be a leader for years to come. 
Via The Motley Fool
Is CRISPR Therapeutics Stock a Buy?
The gene-editing therapy specialist is rising in prominence. 
Via The Motley Fool
The 2030 Millionaire’s Club: 3 Biotech Stocks to Buy Now
With interest cuts on the horizon, it's a prime time to consider these high-risk-high-reward biotech stocks to buy. 
Via InvestorPlace
7 Must-Buy Stocks if You Only Have $1,000 to Spend: May Edition
With a modest $1,000 investment, these stocks offer the potential for market-beating gains through solid fundamentals and growth prospects. 
Via InvestorPlace
Bull Market Buys: 2 Growth Stocks to Own for the Long Run
These biotech stocks have just launched their first products. 
Via The Motley Fool
Wall Street Favorites: 3 Biotech Stocks with Strong Buy Ratings for May 2024
With new innovation, millions of retiring baby boomers, and an increase in mergers, biotech stocks to buy have a good deal of upside ahead. 
Via InvestorPlace
7 No-Brainer Stocks to Buy and Hold for the Next 20 Years: May 2024
Here are seven stocks to buy and hold that are poised for long-term growth over the next 20 years and can future-proof your portfolio. 
Via InvestorPlace
Is CRISPR Stock Going to $95? 1 Wall Street Analyst Thinks So.
How much would you pay for a stock that might earn $25 a year in six years? 
Via The Motley Fool
2 Healthcare Stocks to Buy and Hold for Great Long-Term Potential
These healthcare stocks offer completely different approaches to long-term investment gains. 
Via The Motley Fool
The 3 Best Cathie Wood Stocks to Buy in May 2024
Cathie Wood takes a very risky approach to investing, but she has plenty of great picks. Here are some of the best Cathie Wood stocks to buy. 
Via InvestorPlace
The 3 Most Undervalued Biotech Stocks to Buy in May 2024
Three most undervalued biotech stocks to buy now will take off in the coming years and bring back continuous, hefty returns. 
Via InvestorPlace
Genomics Game-Changers: 3 Stocks Unlocking the Secrets of Life
Genomics is the future of medicine, creating big opportunity for some of the top genomics stock picks to buy today. 
Via InvestorPlace
Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine
These biotech breakthrough stocks give investors a glimpse into medicine's future -- and massive moneymaking opportunities to boot. 
Via InvestorPlace
CRSP Stock Earnings: CRISPR Therapeutics Misses EPS, Misses Revenue for Q1 2024
CRSP stock results show that CRISPR Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
3 Biotech Stocks With the Potential to Make You an Overnight Millionaire
Don’t miss out on these stocks that could rock your portfolio with massive growth following FDA approvals and breakthrough treatments. 
Via InvestorPlace
Exposures Product Safety
Shhh! 3 Secret Gene Editing Stocks Flying Below Wall Street’s Radar
The gene editing stocks are worth tuning into as some investors out there discount their innovative, albeit early-stage pipelines. 
Via InvestorPlace
3 Growth Stocks You’ll Kick Yourself for Not Buying Today
Netflix, Intuit, and Vertex Pharmaceuticals are three growth stocks to buy, each positioned for significant market share and returns. 
Via InvestorPlace
3 Biotech Stocks to Buy and Hold Through 2030 and Beyond
It pays to develop novel medicines for life-threatening illnesses. 
Via The Motley Fool
3 Gene Editing Stocks with the Potential to Make You an Overnight Millionaire
Pay close attention to gene editing stocks. By 2028, according to MarketsandMarkets, the market could be worth about $10.6 billion. 
Via InvestorPlace
Stock Market Crash Alert: 3 Must-Buy Biotech Stocks When Prices Plunge
A slip in the market could give investors a rare opportunity to get some top biotech stocks to buy at a considerable discount. 
Via InvestorPlace
Missed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon.
Good news could be just around the corner for two drugmakers not named Novo Nordisk. 
Via The Motley Fool
Vertex Pharmaceuticals Just Made 2 Big Moves. Is the Stock a Buy?
Vertex is broadening its portfolio. 
Via The Motley Fool
3 Magnificent Stocks That Could Double or More by 2030
There's no guarantee these stocks will double by 2030, but their growth prospects look great. 
Via The Motley Fool
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for April 2024
In a stock picker’s market, here are three biotech stocks analysts believe have a chance to outperform the market in 2024. 
Via InvestorPlace
Better Buy: CRISPR Therapeutics Vs. Viking Therapeutics
These rising drugmakers have serious arguments in their favor. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
29 30 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.